Alessandra Tucci | Personalized Medicine | Women Researcher Award

Published on by Top Pharmaceutical

Alessandra Tucci | Personalized Medicine | Women Researcher Award

Dr. Alessandra Tucci, ASST Spedali Civili di Brescia, Italy

Dr. Alessandra Tucci is an esteemed Italian hematologist and Director of the Hematology Unit at ASST Spedali Civili di Brescia. With over three decades of expertise, she specializes in lymphomas, particularly in elderly patients. She holds dual specializations in Allergology & Immunology (University of Florence) and Hematology (University of Milan). A key figure in national and international research, she has led multiple clinical trials and serves on prestigious scientific boards, including the Italian Lymphoma Foundation (FIL) and European Hematology Association (EHA). An accomplished author and peer reviewer, Dr. Tucci continues to advance hematological research.

Publication Profile

Scopus

Education

Dr. Alessandra Tucci 🎓 earned her Doctor of Medicine degree from the University of Brescia in 1987, specializing in Allergology, Immunology, and Hematology. 🩸 Her dual specialization underscores her deep expertise in blood disorders and immune-related conditions. 🏥 Passionate about advancing medical science, she further pursued a Master’s in Management applied to hematology, showcasing her leadership in clinical and research settings. 📚 With a strong foundation in both patient care and scientific innovation, Dr. Tucci continues to make significant contributions to the field, bridging the gap between medical research and practical healthcare solutions. 🔬✨

Experience

Dr. Alessandra Tucci 🔬 is a Principal Investigator in numerous national and international studies, focusing on hematology, particularly lymphomas and hematologic malignancies in elderly patients. 🩸 Her research impact is evident through an impressive H-index of 44 (Scopus) and 48 (Google Scholar), with over 9,792 citations. 📊 She has contributed as a Guest Editor for Special Issues in high-impact journals like Cancers and serves as a reviewer for prestigious publications such as Lancet Haematology and Blood Advances. 📖 Her dedication to advancing hematologic research continues to shape the field and improve patient outcomes worldwide.

Awards

Dr. Alessandra Tucci 🏆 has played a pivotal role in clinical trials (phases I-III), driving innovative treatments in hematology and significantly improving patient care. 🩸 Her contributions extend beyond research, as she actively shapes the scientific community through editorial work, peer reviews, and participation in prestigious scientific boards. 📖🔬 Recognized for her expertise and leadership, she is a respected thought leader whose work influences both clinical practice and future therapeutic advancements. 🌍✨ Through her dedication, Dr. Tucci continues to leave a lasting impact on the field of hematology, inspiring researchers and improving patient outcomes worldwide. 💡👩‍⚕️

Research Focus

Dr. Alessandra Tucci is a distinguished researcher specializing in hematology 🩸, with a focus on lymphomas 🦠, leukemias 🧬, and stem cell transplantation 🏥. Her work extensively explores invasive pulmonary aspergillosis in leukemia, mantle cell lymphoma prognosis, and the impact of radiotherapy on hematologic malignancies. She contributes to clinical trials, geriatric oncology assessments, and advanced imaging techniques like FDG PET/CT 📡 to improve diagnostic precision and treatment outcomes. Dr. Tucci’s research plays a critical role in optimizing chemoimmunotherapy 💉 and personalized medicine for hematologic disorders.

Publication Top Notes

Different Epidemiology of Invasive Pulmonary Aspergillosis in Acute Lymphoblastic Leukemia in Comparison With Acute Myeloid Leukemia: Results of a Prospective Multicentric Observational Study of the Rete Ematologica Lombarda

Impact of the Number of Administered Systemic Treatment Lines on Local Response to Radiation Therapy for Multiple Myeloma

A phase 2 study of autologous stem cell transplantation as salvage therapy for older patients with aggressive B-cell lymphoma prospectively evaluated by comprehensive geriatric assessment: the FIL_RECANZ study

Prognostic Role of Pretreatment Tumor Burden and Dissemination Features From 2-[18F]FDG PET/CT in Advanced Mantle Cell Lymphoma

Early progression beyond first-line chemoimmunotherapy in follicular lymphoma: Insights from a Fondazione Italiana Linfoma (FIL) study

Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results

Correction: Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19 (Genome Medicine, (2023), 15, 1, (22), 10.1186/s13073-023-01173-8)

Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection

Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trial
2-[18]F FDG PET/CT dissemination features in adult burkitt lymphoma Are predictive of outcome

Georgina Pamela Coló | Gene Therapy | Best Researcher Award

Published on by Top Pharmaceutical

Georgina Pamela Coló | Gene Therapy | Best Researcher Award

Dr. Georgina Pamela Coló, INIBIBB-CONICET, Argentina

Dr. Georgina Pamela Coló is a distinguished molecular biologist specializing in cancer research. She earned her Ph.D. in Molecular Biology from the University of Buenos Aires (2007, Summa Cum Laude) and holds an MS in Biotechnology from Quilmes National University. Currently a Scientific Researcher at CONICET’s Instituto de Investigaciones Bioquímicas (INIBIBB) in Argentina, she also leads a Max Planck Institute partner group. Her research focuses on cancer progression and therapeutic innovations. With extensive international experience in Germany, Spain, and the U.S., Dr. Coló has authored impactful publications in top-tier journals.

Publication Profile

Scopus

Education

Dr. Georgina Pamela Coló 🎓 is a distinguished molecular biologist with a Ph.D. from the University of Buenos Aires, School of Sciences (2003-2007), where she graduated summa cum laude (10/10) under the mentorship of Dr. M.A. Costas. Prior to her doctorate, she earned an M.S. in Biotechnology (8.74/10) from Quilmes National University (1998-2002). Her academic journey began with a B.Sc. in Science and Technology (1998-2000) and training as a Laboratory Technician 🔬. With a strong foundation in biotechnology and molecular biology, Dr. Coló has made significant contributions to scientific research and innovation. 🧬✨

Experience

Dr. Georgina Pamela Coló 🧬 is a dedicated cancer researcher currently serving as a Scientific Researcher at CONICET (2024-present) at the Instituto de Investigaciones Bioquímicas (INIBIBB), Argentina. She previously worked as an Assistant Researcher (2019-2024) under Dr. Curino. Since 2018, she has led a Max-Planck-Institute partner group 🇩🇪 with Dr. Prof. Reinhard Fässler. Her career includes research fellowships in Spain 🇪🇸 and Germany, as well as postdoctoral studies at INIBIBB, Max-Planck-Institute, and CIB-CSIC. With extensive experience in molecular medicine and cancer biology 🔬, Dr. Coló continues to make groundbreaking contributions to biomedical research. ✨

Awards

Dr. Georgina Pamela Coló 🏆 has received numerous prestigious awards for her outstanding contributions to biomedical research. In 2021, she won the Best Poster Award 🖼️ at the Reunión de Sociedades de Biociencias in Argentina. She was honored with the JCI TOYP Award (2020) for scientific and technological development. In 2019, she received the Lucio Cherny Award for interdisciplinary research 🧬. Her accolades include the Best Poster Award (2018), multiple CONICET fellowships 🎓, and the Max Planck postdoctoral fellowship (2013-2016). Dr. Coló’s impactful research continues to be recognized on both national and international levels.

Research Focus

Dr. Georgina Pamela Coló is a researcher specializing in nanomedicine 🧪, oncology 🎗️, and proteomics 🧬. Her work focuses on amorphous silica nanoparticles and their antitumor activity in triple-negative breast cancer cells 🏥. She also investigates the proteomic effects of hemin in breast cancer, exploring molecular pathways and therapeutic targets. Her research integrates nanotechnology 🏗️ and biochemistry to develop innovative cancer treatments. Through cutting-edge proteomic analysis, she contributes to personalized medicine and targeted drug delivery 🎯. Her studies are highly relevant to pharmaceutical sciences 💊 and biomedical research 🔬, advancing potential cancer therapies.

Publication Top Notes

Amorphous silica nanoparticles exhibit antitumor activity in triple-negative breast cancer cells

Proteomic analysis of the effect of hemin in breast cancer

Yu Liu | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Yu Liu | Drug Discovery and Development | Best Researcher Award

Mr. Yu Liu, China Institute of Pharmaceutical Industry Co., Ltd, China

Dr. Liu Yu (b. January 11, 1981, Hengyang, Hunan) is a distinguished researcher and doctoral supervisor specializing in medicinal chemistry. He earned his Ph.D. from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences (2011). Currently, he serves as Deputy Director at the China National Institute for the Control of Pharmaceutical and Biological Products and the Shanghai Drug Synthesis Process Engineering Technology Research Center. He is also a standing committee member of the Health Economics Theory and Policy Committee. Dr. Liu plays a pivotal role in pharmaceutical research and technology transfer in China.

Publication Profile

Scopus

Education

Mr. Yu Liu pursued his education in Medicinal Chemistry 🧪 at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences 🎓. He was enrolled as a full-time student from September 2008 to July 2011 📅. During this period, he dedicated himself to advanced research in the field, ultimately earning a Doctorate degree 🎖️. His studies focused on the development of medicinal compounds and pharmaceutical innovations, contributing to the field of drug discovery and development 💊. With a strong academic foundation, Mr. Liu gained expertise in chemical synthesis and pharmacology, preparing him for a successful career in medicinal sciences 🔬.

Professional Leadership

Mr. Yu Liu serves as the Deputy Director 🏛️ at both the Technology Transfer Center, China National Institute for the Control of Pharmaceutical and Biological Products and the Shanghai Drug Synthesis Process Engineering Technology Research Center 🔬. In these roles, he plays a pivotal part in advancing pharmaceutical and biotechnology research 💊. His leadership drives innovation in drug development and synthesis, ensuring progress in the field of medicinal chemistry 🧪. With his extensive expertise, Mr. Liu significantly contributes to technology transfer, regulatory advancements, and pharmaceutical innovation, reinforcing his influence in the global healthcare industry 🌍.

Experience

Mr. Yu Liu is an esteemed member of high-level academic committees 🏛️, including the Standing Committee of the Health Economics Theory and Policy Professional Committee under the Chinese Association of Health Economics 📊. His active participation in these organizations reflects his dedication to bridging scientific innovation and economic policy in healthcare 💡💰. By contributing to policy development and strategic decision-making, he plays a crucial role in shaping the future of health economics and pharmaceutical advancements 💊. His interdisciplinary expertise ensures a significant impact on both scientific research and economic frameworks, fostering innovation in healthcare systems 🌍.

Research Focus

Yu Liu’s research focuses on analytical chemistry, particularly in pharmaceutical analysis. His expertise lies in the development and validation of advanced chromatographic techniques, such as GC (Gas Chromatography) and HPLC-RID (High-Performance Liquid Chromatography with Refractive Index Detection). His work involves identifying and quantifying related substances in pharmaceutical compounds, including novel impurities in tetrabenazine. His contributions ensure drug purity, safety, and efficacy, making a significant impact on quality control and regulatory compliance in the pharmaceutical industry. His research bridges analytical chemistry and pharmaceutical sciences, advancing drug formulation and safety.

Publication Top Notes

GC and HPLC-RID method development and validation for the determination of twelve related substances, including several novel compounds in tetrabenazine

Annik Caliezi | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Annik Caliezi | Clinical Trials | Best Researcher Award

Ms. Annik Caliezi, Dermatologie Inselspital, Switzerland

Annik Caliezi is a dedicated medical student in her 10th semester of the Master of Medicine program at the University of Bern. She holds a Bachelor’s in Medicine and a bilingual Matura in Economics and Law. With hands-on experience as a nursing assistant at Careanesth and an OR assistant in hand surgery, Annik has also contributed to histology and anatomy education. Her research focuses on Hidradenitis Suppurativa and its impact on sexual quality of life, with publications in MDPI. Fluent in German, English, and French, she holds multiple life support certifications. 🔬📚

Publication Profile

orcid

Education

Ms. Annik Caliezi 🎓 is currently in the 10th semester of her Master of Medicine at the University of Bern 🏥, where she has been pursuing her studies since 2023. Prior to this, she completed her Bachelor of Medicine (2020–2023) at the same institution, building a strong foundation in medical sciences 🔬. Her academic journey began with a bilingual Matura in Economics and Law 📚⚖️ at Gymnasium Kirchenfeld Bern (2015–2019), where she developed analytical and interdisciplinary skills. With a passion for medicine and a commitment to excellence, she continues to advance in her medical education and training. 🚀

Experience

Ms. Annik Caliezi 🏥 has gained diverse work experience in healthcare and beyond. Since May 2024, she has been working as a nursing assistant at Careanesth 🩺, and since May 2023, she has served as an OR Assistant in Hand Surgery at Permanence Hospital Hirslanden Bern ✋🏽🔬. Previously, she assisted in histology and anatomy courses at the University of Bern (10/2022–05/2023) 🧫📚. Since December 2021, she has been interning at Bahnhofpraxis Wichtrach 🚑. Her earlier experiences include a geriatric rehabilitation internship (2021) 👵🏼, a role as a waitress (2019–2020) ☕, and an activity therapy internship (2018) 🏡.

Awards

Ms. Annik Caliezi 🏥 has earned several valuable certifications in healthcare and language proficiency. In 2024, she became an Immediate Life Support (ILS) Provider through the European Resuscitation Council 🚑. She also completed the French course “Français pour futur médecin” (2023) 🩺🇫🇷, enhancing her medical communication skills. Additionally, she holds Basic Life Support (BLS) Provider certifications from 2021 and 2022 🏥🆘. Beyond medical training, she achieved Cambridge English Advanced (C1) – Grade A in 2019 📖🇬🇧. These certifications reflect her commitment to excellence in both emergency care and multilingual communication in the medical field. 🚀

Research Focus

Ms. Annik Caliezi’s research primarily focuses on dermatology 🩺, with a specific emphasis on hidradenitis suppurativa (HS) 🔬, a chronic inflammatory skin disease. Her work examines the impact of HS on sexual quality of life ❤️, addressing the psychological, emotional, and physical challenges faced by patients. Through her studies, she highlights the burden of HS 🤕, emphasizing the need for better patient care, awareness, and treatment strategies 📢. Her research contributes to dermatological advancements, aiming to improve both clinical outcomes and overall well-being 😊 for individuals affected by this debilitating condition.

Publication Top Notes

Impact of Hidradenitis Suppurativa on Sexual Quality of Life

Michael Harrison | Precision Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Michael Harrison | Precision Medicine | Best Researcher Award

Dr. Michael Harrison, UCSF, United States

Dr. Michael Harrison is a pioneering pediatric surgeon and fetal therapy expert. 🎓 He earned his B.A. from Yale (1965) and M.D. from Harvard Medical School (1969), followed by extensive surgical training at Massachusetts General Hospital and fellowships in pediatric surgery. 🏥 He joined UCSF in 1978, where he became a Full Professor and founded the Fetal Treatment Center. 👶 His groundbreaking work in fetal surgery has earned him numerous accolades, including the Golden Plate Award and presidency of the International Fetal Medicine and Surgery Society. 🌍 Now Professor Emeritus at UCSF, he continues to shape the field of pediatric surgery. ✨

Publication Profile

Scopus

Education

Dr. Michael Harrison 🎓 began his academic journey at Yale University (1961-1965), earning a B.A. before pursuing his M.D. in Medicine at Harvard Medical School (1965-1969) 🏥. He completed his surgical residency at Massachusetts General Hospital (1969-1971) and advanced his expertise as a Postdoctoral Fellow in Allergy & Immunology at the National Institute of Allergy and Infectious Disease (1971-1973) 🧬. Returning to Massachusetts General, he served as a Senior Resident (1973-1974) and Chief Resident (1974-1975) 🔬. Further specializing, he completed fellowships in Pediatric Surgery at Rikshospitalet (1975-1976) 🇳🇴 and Children’s Hospital of Los Angeles (1976-1978) 👶🩺.

Experience

Dr. Michael Harrison 🏥 has been a Founding Member of the International Fetal Medicine and Surgery Society (1981-present) 👶 and has served as its President at the Annual Meeting (1989, 2006) 🎤. He has contributed as a Committee Member for the Medical Advisory Committee of the American Association of Tissue Banks (1993-present) 🧬 and chaired the Committee on Fetal Therapy at APSA (1994-1996) 🏥. A Board Member of the International Society of the Fetus as Patient (1997-present) 🌍, he also consults for the MOMS study (2003-present) 🤰. Since 2010, he has been Vice President of the California Academy of Medicine 📚.

Awards

Dr. Michael Harrison 🏅 has received numerous prestigious honors, including the Golden Plate Award (1982, 1988) 🏆, the William E. Ladd Medal (2010) 🏅, and the Lifetime Achievement Award (2011) 🌟 from the International Fetal Medicine and Surgery Society. He was elected to the Institute of Medicine (2009) 📜 and honored with the Denis Browne Gold Medal (2013) 🏵️. As a celebrated lecturer, he has delivered keynote addresses worldwide 🌍, including at the Nobel Minisymposium on Fetal Medicine (1998) 🎤. His groundbreaking contributions in pediatric surgery have earned him global recognition and lasting influence in the field.

Research Focus

Dr. Michael R. Harrison is a pioneering surgeon and researcher in pediatric surgery and fetal therapy 🏥👶. His work focuses on maternal-fetal surgery, particularly for conditions like esophageal atresia and diaphragmatic hernia. He has contributed to the development of magnetic compression anastomosis 🧲 and other innovative minimally invasive surgical devices 🔬. His research advances the treatment of complex congenital disorders and improves outcomes for newborns. With numerous publications, he has significantly impacted pediatric device clinical trials 📊. Dr. Harrison’s groundbreaking contributions continue to shape the future of pediatric and fetal surgical care 🚼✨.

Publication Top Notes

Pediatric Device Clinical Trials Activity: 1999–2022

Lessons Learned From the First-In-Human Compassionate Use of Connect-EA™ in Ten Patients With Esophageal Atresia

Evaluation of a Magnetic Compression Anastomosis for Jejunoileal Partial Diversion in Rhesus Macaques

Sonographic Predictors of Survival in Fetal Diaphragmatic Hernia

Beyond the gut: spectrum of magnetic surgery devices

The Rearing of Maternal–Fetal Surgery: The Maturation of a Field from Conception to Adulthood

The novel application of an emerging device for salvage of primary repair in high-risk complex esophageal atresia

Esophageal Magnetic Compression Anastomosis in Esophageal Atresia Repair: A PRISMA-Compliant Systematic Review and Comparison with a Novel Approach

An experimental study on long term outcomes after magnetic esophageal compression anastomosis in piglets

Novel device for endoluminal esophageal atresia repair: First-in-human experience

Fatimazahra Sayerh | Antibiotic Resistance | Women Researcher Award

Published on by Top Pharmaceutical

Fatimazahra Sayerh | Antibiotic Resistance | Women Researcher Award

Mrs. Fatimazahra Sayerh, Faculty of Science and Technology of Mohammedia, Hassan II University, Casablanca, Morocco, Morocco

Fatimazahra Sayerh 🌍🔬 is an environmental science researcher and QHSE specialist with extensive academic and professional experience. She is currently pursuing a Doctorate in Environmental Sciences at Faculté des Sciences et Techniques de Mohammedia (2021-present) after earning a Master’s in Environmental Science and Management (2019-2021) and a Bachelor’s in Water and Environmental Engineering (2018-2019). Fatimazahra has conducted microbiological water analysis at the Institut National d’Hygiène, Rabat, trained professionals in QHSE at Cabinet Certinormes, and contributed to water quality studies at Lydec, Casablanca. She holds a QHSE certification and specializes in water analysis and environmental risk management.

Publication Profile

Scopus

Education

Mrs. Fatimazahra Sayerh has established a strong academic background in environmental sciences 🌍. Her journey began with a Baccalauréat in Physics and Chemistry (2015) followed by a DEUST in Mathematics, Computer Science, and Physics (2015-2018) 💻. She then earned a Bachelor’s in Water and Environmental Engineering (2018-2019) 💧 and a Master’s in Environmental Sciences and Management (2019-2021) 🌱. Currently, she is pursuing a Doctorate in Environmental Sciences (2021-present) at the Faculty of Sciences and Techniques, Mohammedia 🎓. Her diverse academic path reflects her dedication to sustainability and scientific research for a greener future 🌿.

Professional Experience

Mrs. Fatimazahra Sayerh has gained extensive research and professional experience in environmental sciences 🌍. She conducted a research internship at the National Institute of Hygiene, Rabat (Dec 2022 – July 2024) 🏥, specializing in microbiological water analysis 💧. As a trainer at Cabinet Certinormes, Casablanca (Sept 2022 – Dec 2022) 📚she provided QHSE training. Her final-year research projects included physico-chemical water analysis at LNSEP Laboratory, Rabat (April 2021 – July 2021) ⚗️ and efficiency calculations and leakage analysis at Lydec, Casablanca (April 2019 – June 2019) 💦, contributing to sustainable water management and environmental health.

Research Focus

Mrs. Fatimazahra Sayerh specializes in microbiology, environmental health, and antibiotic resistance. Her research focuses on the analysis of pathogenic microorganisms in hospital effluents, utilizing statistical approaches to assess antibiotic resistance patterns and their impact on public health and ecosystems. Through advanced microbial analysis and bioinformatics, she aims to identify critical environmental health risks associated with wastewater contamination. Her work bridges the gap between clinical microbiology and environmental sciences, contributing to sustainable public health strategies and antimicrobial stewardship. Her expertise is essential in combating the rising threat of multidrug-resistant pathogens in aquatic and hospital settings.

Publication Top Notes

Analysis of pathogenic microorganisms in hospital effluents: A statistical approach to understanding antibiotic resistance and environmental health risks

Shuwei Zhou | Gastrointestinal Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Shuwei Zhou | Gastrointestinal Pharmacology | Best Researcher Award

Ms. Shuwei Zhou, Southeast University Zhongda Hospital, China

🔬 Dr. Shuwei Zhou is a distinguished researcher specializing in imaging and nuclear medicine at Zhongda Hospital, Southeast University, China. 🏥 She holds a Ph.D. in Imaging and Nuclear Medicine from Southeast University and a B.A. & Master’s from Hunan University of Chinese Medicine. 🎓 Dr. Zhou has authored numerous high-impact SCI publications 📑 focusing on HCC, LI-RADS, MRI diagnostics, and treatment response. Her contributions include 4 national research projects and 2 patents. 🏆 As a leading expert in radiology and medical imaging, her work advances diagnostic accuracy and patient care in oncology and musculoskeletal disorders. ⚕️✨

Publication Profile

Scopus

Education

Ms. Shuwei Zhou 🎓 has showcased outstanding academic excellence, earning a Ph.D. in Imaging and Nuclear Medicine from the School of Medicine at Southeast University 🏥. Her strong foundation in the field began at Hunan University of Chinese Medicine, where she completed her B.A. and Master’s degree, ranking 1st out of 159 students 🏆. With expertise in molecular and functional imaging, interventional radiology, and pathology 🔬, she has developed a deep understanding of advanced medical diagnostics. Her dedication to research and innovation continues to shape the future of nuclear medicine and imaging technology. 🚀

Experience 

Ms. Shuwei Zhou 🔬 has made significant research contributions, publishing in esteemed journals like the American Journal of Roentgenology, Abdominal Radiology, and Frontiers in Immunology 📚. As the first author, she has led groundbreaking studies on MRI contrast agents, diagnostic performance, and treatment response in hepatocellular carcinoma (HCC) 🏥. Her interdisciplinary expertise extends to osteoporosis prediction, the role of gut microbiota in inflammatory bowel disease, and dual-energy CT for bone mineral density 🦴. Through her innovative research, she continues to advance medical imaging and diagnostic precision, making a lasting impact on the field of nuclear medicine. 🚀

Awards

Ms. Shuwei Zhou 🎓 is a distinguished researcher whose impressive portfolio includes first-author contributions in high-impact journals, leadership in scientific projects, and remarkable interdisciplinary expertise 🔬. Her groundbreaking work in imaging and nuclear medicine, particularly in hepatocellular carcinoma research and diagnostic imaging techniques 🏥, has significantly advanced the field. With a strong commitment to innovation and precision in medical diagnostics, she continues to push the boundaries of research. Her achievements make her a highly deserving candidate for the Best Researcher Award 🏆, recognizing her invaluable contributions to the future of medical imaging and nuclear medicine. 🚀

Research Focus

Shuwei Zhou’s research primarily focuses on medical imaging 🏥📡 and oncology, with a particular emphasis on hepatocellular carcinoma (HCC) 🏨🧬 and non-radiation treatment response assessment. She is actively involved in the development of diagnostic algorithms 📊🔍, such as the LI-RADS Nonradiation Treatment Response Algorithm, and predictive models like the TRACE Model, which help evaluate the effectiveness of transarterial chemoembolization (TACE) 💉⚕️ in patients with unresectable liver cancer. Her contributions aim to enhance precision medicine 🎯 and optimize clinical decision-making for better patient outcomes.

Publication Top Notes

LI-RADS Nonradiation Treatment Response Algorithm Version 2024: Diagnostic Performance and Impact of Ancillary Features

TRACE Model: Predicting Treatment Response to Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma

Xandra Breakefield | Gene Therapy | Best Researcher Award

Published on by Top Pharmaceutical

Xandra Breakefield | Gene Therapy | Best Researcher Award

Prof. Dr. Xandra Breakefield, Massachusetts General Hospital/Harvard Medical School, United States

Prof. Dr. Xandra Breakefield is a pioneering geneticist and neuroscientist specializing in gene therapy and extracellular vesicle research. She earned her Ph.D. from Georgetown University and trained at NIH under Nobel Laureate Dr. Marshall Nirenberg. A Harvard Medical School professor and Massachusetts General Hospital researcher, she has made groundbreaking contributions to neurogenetics and dystonia. Recognized with numerous prestigious awards 🏆, including the Mika Salpeter Lifetime Achievement Award, she ranks among the world’s top scientists. A leader in gene and cell therapy, she serves on advisory boards worldwide 🌍, shaping the future of biomedical research.

Publication Profile

orcid

Education

Prof. Dr. Xandra Breakefield 🎓 embarked on her academic journey with an A.B. in Biology from Wilson College (1960-1965), graduating cum laude for her outstanding performance. During this period, she also enriched her knowledge at American University (1964-1965), deepening her expertise in biology 🧬. Her passion for microbial genetics led her to pursue a Ph.D. at Georgetown University (1967-1971), where she specialized in microbial genetics 🦠. This strong educational foundation set the stage for her groundbreaking contributions to the field, establishing her as a distinguished researcher in genetics and molecular biology. 🌟

Professional Experience

Prof. Dr. Xandra Breakefield 🧬 has had an illustrious career in genetics and neurology. She has been a Geneticist at Massachusetts General Hospital’s Radiology Service since 2002 and a Professor of Neurology at Harvard Medical School since 1996. Previously, she held key roles in molecular neurogenetics at Massachusetts General Hospital 🏥 and directed the Division of Molecular Neurogenetics at the Eunice Kennedy Shriver Center. Her academic journey includes faculty positions at Yale University and Georgetown University 📚. Early in her career, she trained under Nobel Laureate Dr. Marshall Nirenberg at NIH, shaping her expertise in biochemical genetics. 🌟

Awards

Prof. Dr. Xandra Breakefield 🧬 has received numerous prestigious awards for her groundbreaking contributions to neuroscience and genetics. She earned the McKnight Neuroscience Development Award (1982-1984) and two Javits Neuroscience Investigator Awards (1985-1992, 1995-2002). She was honored with an Honorary Doctorate from Wilson College (1991) and an Honorary Master’s Degree from Harvard Medical School (1996) 🎓. Recognized globally, she received the Mika Salpeter Lifetime Achievement Award (2013) and the NIH Director’s WALS Speaker Award (2017). Ranked among the Top 1000 Female Scientists in the World (2022, 2024), her work continues to shape modern molecular medicine. 🌟

Research Focus

Prof. Dr. Xandra O. Breakefield focuses on neuroscience, gene therapy, and extracellular vesicles 🧠🧬🩸. Her research explores how extracellular vesicles facilitate cell-to-cell communication and their potential for delivering gene therapies to treat neurological disorders and cancers. She also investigates glioblastoma, a highly aggressive brain tumor, using cortical organoids 🧪🔬 to study cell-state heterogeneity and intercellular transfer. Her work has significant implications for precision medicine and targeted therapies 🎯💊. As a leading expert in the field, she collaborates on innovative projects integrating genomics, bioengineering, and molecular biology to advance treatments for brain diseases.

Publication Top Notes

Extracellular vesicles for the delivery of gene therapy

Data from Glioblastoma Cortical Organoids Recapitulate Cell-State Heterogeneity and Intercellular Transfer

RNA delivery by extracellular vesicles in mammalian cells and its applications

Versatile Role of Rab27a in Glioma: Effects on Release of Extracellular Vesicles, Cell Viability, and Tumor Progression

Mutant Allele-Specific CRISPR Disruption in DYT1 Dystonia Fibroblasts Restores Cell Function

Exosome/microvesicle content is altered in leucine‐rich repeat kinase 2 mutant induced pluripotent stem cell‐derived neural cells

Glioma-Derived miRNA-Containing Extracellular Vesicles Induce Angiogenesis by Reprogramming Brain Endothelial Cells

Reda Abdel-Hameed | Pharmaceutical Chemistry | Best Researcher Award

Published on by Top Pharmaceutical

Reda Abdel-Hameed | Pharmaceutical Chemistry | Best Researcher Award

Prof. Dr. Reda Abdel-Hameed, University of Hail, Egypt

Prof. Dr. Reda Abdel-Hameed is a distinguished chemist specializing in applied physical chemistry. He earned his B.Sc. (1998), M.Sc. (2003), and Ph.D. (2006) from Al-Azhar University, Cairo. With over two decades in academia, he has served as a professor at Al-Azhar University and an associate professor at the University of Hail, Saudi Arabia. His prolific research includes 134 published papers on nanotechnology, drug design, and environmental chemistry. A leader in scientific innovation, he continues to shape the future of chemistry through groundbreaking studies and mentorship.

Publication Profile

Google Scholar

Education

Prof. Dr. Reda Abdel-Hameed 🎓 is a distinguished chemist with a strong academic background. He earned his B.Sc. in Chemistry in 1998 with an Excellent with Honor degree 🏅, followed by an M.Sc. in Applied Organic Chemistry in 2003 and a Ph.D. in Applied Physical Chemistry in 2006. His academic career began as a Demonstrator at Al-Azhar University (1998-2003) and progressed to Lecturer (2003-2006), Assistant Professor (2006-2012), and Associate Professor (2012-2017). He also served at Hail University, KSA (2009-2012). Since 2017, he has been a Full Professor at Al-Azhar University, contributing significantly to the field of chemistry 🔬.

Experience 

Prof. Dr. Reda Abdel-Hameed 📚 has an extensive teaching portfolio in chemistry across Al-Azhar University and Hail University. At Al-Azhar, he has taught courses in Physical Chemistry, Electrochemistry, Polymer Science, Industrial Chemistry, and more 🔬. At Hail University, he covered Applied Physical Chemistry, Quantum Chemistry, Medical Chemistry, and Petroleum Chemistry ⛽. Additionally, he played a key role in developing course specifications and descriptions. His contributions extend to authorship, with books like Introduction to Organic Chemistry, Applied Electrochemistry, and Nanocomposites as Corrosion Inhibitors 📖. His dedication to chemistry education continues to inspire students worldwide 🌍.

Awards

Prof. Dr. Reda Abdel-Hameed 🌍 is a globally recognized scientist, ranked among the world’s top 2% by Stanford University and Elsevier from 2019 to 2023 📊. His excellence in academia has earned him numerous accolades, including the Ideal Student Prize (1996-1997) 🏆, the Faculty of Science Award for Academic Affairs (2012), and the Excellence in Teaching Award (2017) 🎓. He was also honored for integrating technology into higher education (2010) and recognized as the Best Coordinator for Student Activities at Hail University (2016). A proud member of the Royal Society of Chemistry (RSC) 🔬, he continues to make remarkable contributions.

Research Focus

Prof. Dr. Reda S. Abdel-Hameed specializes in corrosion science and electrochemical applications ⚡🔬. His research focuses on developing corrosion inhibitors 🛡️ for metals, particularly in acidic and marine environments. He explores green chemistry approaches 🌱, including eco-friendly inhibitors derived from expired drugs 💊, polymers 🏗️, and heterocyclic compounds 🧪. His work advances electrochemical techniques for evaluating materials’ durability and protection in industrial applications 🏭. With significant contributions to nanotechnology-based inhibitors 🧬 and adsorption studies, his research benefits sectors like petrochemicals, metallurgy, and coatings 🏗️. His expertise in analytical electrochemistry helps mitigate corrosion-related challenges, ensuring sustainability and efficiency.

Publication Top Notes

Analytical application using modern electrochemical techniques

Ranitidine drugs as non-toxic corrosion inhibitors for mild steel in hydrochloric acid medium

Preparation of green cardanol-based epoxy and hardener as primer coatings for petroleum and gas steel in marine environment

Aminolysis of polyethylene terephthalate waste as corrosion inhibitor for carbon steel in HCl corrosive medium

Effect of expired drugs as corrosion inhibitors for carbon steel in 1M HCL solution

2-(2, 6-dichloranilino) phenyl acetic acid drugs as eco-friendly corrosion inhibitors for mild steel in 1M HCl

Expired Voltaren drugs as corrosion inhibitor for aluminium in hydrochloric acid

Nano-composite as corrosion inhibitors for steel alloys in different corrosive media

Corrosion inhibition and adsorption properties of some heterocyclic derivatives on C-steel surface in HCl

Bekri Melka Abdo | Drug Discovery and Development | Top Pharmaceutical Scientist Award

Published on by Top Pharmaceutical

Bekri Melka Abdo | Drug Discovery and Development | Top Pharmaceutical Scientist Award

Mr. Bekri Melka Abdo, Ethiopian Institute of Agricultural Research, Ethiopia

Bekri Melka Abdo is a dedicated organic chemist specializing in natural product chemistry 🌿. With expertise in plant sample collection, extraction, compound isolation, and structure elucidation, he focuses on bioactive compounds from Ethiopia’s medicinal and aromatic plants. His research contributes to developing natural product-based treatments for leishmaniasis 🦠. He has two published journal articles, an h-index of 7, a Google patent, and an ISBN-registered book 📖. Actively engaged in research and consultancy, Bekri is committed to innovative drug discovery and advancing natural product chemistry for global health.

Publication Profile

orcid

Education

Bekri Melka Abdo is a dedicated professional in organic chemistry 🧪, specializing in natural product chemistry 🌿. His expertise encompasses plant sample collection and preparation, extraction, compound isolation, and structure elucidation. He is skilled in qualitative and quantitative analysis, as well as biological activity determination of natural products extracted from various aromatic and medicinally significant 🌱 exotic and endemic plant species of Ethiopia. With a strong foundation in the field, he contributes to the discovery and characterization of bioactive compounds, supporting advancements in medicine, pharmaceuticals, and biotechnology 🔬. His research plays a vital role in exploring Ethiopia’s rich botanical resources.

Experience 

Bekri Melka Abdo is a passionate researcher in natural product chemistry 🌿, with a strong track record of research and innovation 🔬. He has successfully completed two research projects and maintains an h-index of 7 📊. His contributions extend to industry consultancy and collaborative projects, showcasing his impact in the field. He has authored a book with an ISBN 📖 and has a Google patent pending. His work is recognized in SCI and Scopus-indexed journals 🏅, with two publications. Actively engaged in editorial roles and professional memberships, he continues to drive scientific advancements in bioactive compound discovery.

Award

Bekri Melka Abdo, with his early career achievements and promising research in natural product chemistry 🌿, is an ideal candidate for the Young Scientist Award 🏆. His dedication to bioactive compound discovery, coupled with his impactful contributions to scientific research and innovation 🔬, highlights his potential for future breakthroughs. With a strong foundation in natural product extraction, analysis, and biological activity determination, he is paving the way for new discoveries in medicine and biotechnology 💊. This award category recognizes emerging researchers like Mr. Abdo, whose work demonstrates both excellence and the promise of transformative scientific advancements.

Research Focus

Mr. Bekri Melka Abdo specializes in phytochemistry and antiparasitic drug discovery, focusing on the bioassay-guided isolation of natural compounds for therapeutic applications. His research on dehydrocostus lactone from Echinops kebericho highlights its potential as a leishmanicidal drug 🦟⚕️. His work integrates natural product chemistry, pharmacognosy, and infectious disease research, contributing to novel drug development against leishmaniasis. By combining traditional medicinal plants with modern bioassays, he advances the search for effective, plant-derived antiparasitic treatments 🌱🔬. His research holds promise for addressing neglected tropical diseases through sustainable and nature-inspired therapies.

Publication Top Notes

Bioassay-guided isolation of dehydrocostus lactone from Echinops kebericho as a leishmanicidal drug